Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi’s Subsidiary Starts Biomarker Discovery Research in the US
December 16, 2011
- ReproCELL to Commercialize World’s 1st iPS Cell-Derived Hepatocytes in April
December 16, 2011
- Janssen Voluntarily Recalls Risperdal Tablet 1 mg
December 15, 2011
- Ibandronate Shows Non-inferiority to Risedronate: Chugai, Taisho
December 15, 2011
- Over 60% of Doctors Support Exclusion of Anticancer Drugs from Current Relief System: CareNet
December 15, 2011
- Ono Enters into Joint Research Agreement with US Company to Discover Antagonists for GPCR Target
December 14, 2011
- MTPC to Seek Strategic Alliance to Expand Generics Business: President Tsuchiya
December 14, 2011
- GSK Submits NDA for Pazopanib in Japan
December 14, 2011
- MTPC to Focus on Development of Global Human Resources
December 14, 2011
- Eisai Files Application for New Aricept Dry Syrup Formulation
December 14, 2011
- SGN-35 for Treatment-naïve Lymphoma to Progress to PIII: Takeda
December 14, 2011
- Substance Patent for Therapeutic Protein Delivery Allowed in US: NanoCarrier
December 14, 2011
- PI/II Results Confirm Safety, Tolerability of Oral Proteasome Inhibitor: Takeda
December 14, 2011
- 86% of Patients Show Objective Responses in PII Trial of CD30 Monoclonal Antibody: Takeda
December 14, 2011
- Mochida Pharmaceutical Grants Rights for Diabetes Treatment to US Merck
December 13, 2011
- Kissei Pharmaceutical to Transfer Marketing Rights for CABASER to Pfizer Japan
December 13, 2011
- Otsuka's US Subsidiary CEO to Become New President, Taiho Pharmaceutical
December 13, 2011
- Wholesalers Eager to Begin Category-Based Price Negotiations After FY2012 Price Revision
December 13, 2011
- Ohara Pharmaceutical to Initiate Clinical Trials for Leukemia Treatment Drug Requested for Development
December 13, 2011
- OncoTherapy’s Subsidiary Immunas Receives Milestone Payment from Kyowa Hakko Kirin
December 13, 2011
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…